brand logo

Am Fam Physician. 2005;72(12):2436

The article “Ethinyl Estradiol/Levonorgestrel (Seasonale) for Oral Contraception” (“STEPS,” April 15, 2005, page 1581) incorrectly referred to the intravaginal combination contraceptive device (NuvaRing) as an oral contraceptive and listed 12 rather than one to two for the number of pregnancies expected per 100 women each year who are using this product. In the first paragraph on page 1582, the second sentence should state, “According to the U.S. Food and Drug Administration, the number of pregnancies expected per 100 women each year are: less than one for intramuscular medroxyprogesterone (Depo-Provera); one for transdermal (Ortho Evra) and combined oral contraceptives; one to two for intravaginal combined contraceptives (NuvaRing); and two for progestin-only pills and ethinyl estradiol/levonorgestrel.” The online version of this article has been corrected.

Continue Reading

More in AFP

Copyright © 2005 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.